Expanded Access to Provide BAY2927088 for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Sponsor: Bayer

Expanded Access
Sponsor score: 60

ClinicalTrials ID:NCT06761976

This Expanded Access Program provides BAY2927088, an oral drug taken twice daily, to patients with advanced NSCLC with HER2 mutations who lack other treatment options. Eligibility is limited to those with no alternative therapies available. The program aims to offer access to this investigational treatment under specific conditions.

Patient Parameters

Program Overview

The purpose of this Expanded Access Program (EAP) is to allow patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option, to receive BAY2927088.

Eligibility Criteria

Get This Program In Your Inbox

You can sign up and apply your patients for this program.